ECIAOTCSurgical & Medical Instruments & ApparatusFiscal year ends March 31
ENCISION INC
Financials through Q2 FY2026, quarter ended Sep 30, 2025Last filing: 10-Q on Nov 13, 2025
$0.01+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $163.15K
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
53.6%+1.4 pts over 5 years
Operating margin
-2.6%−0.6 pts over 5 years
Net margin
-3.4%−0.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -0.5% | -5.1% | -3.1% | -3.8% | |
| Gross profit | +12.0% | -2.5% | -2.6% | -2.9% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -30.7% | -8.7% | -12.7% | |
| Return on assets | -20.6% | -4.9% | -5.9% | |
| Current ratio | 2.33 | 2.10 | 1.66 | |
| Interest coverage | – | – | -3.9× | |
| Inventory turnover | 2.3× | 2.4× | 2.1× | |
| Capex to revenue | 0.8% | 0.6% | 0.8% | |
| Diluted shares | 11M | 12M | 12M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Encision generated $1.73M from operations and spent $287.30K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$1.73M
Used
$287.30K
Capital expenditure$287.30K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-3.4%
×Asset turnover1.75×
×Equity multiplier2.15×
=Return on equity, FY2025-12.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -3.4% | 1.75× | 2.15× | -12.7% |
| FY2024 | -10.5% | 1.66× | 1.84× | -32.0% |
| FY2023 | -4.4% | 1.65× | 1.70× | -12.4% |
| FY2022 | -0.9% | 1.47× | 1.88× | -2.4% |
| FY2021 | 7.8% | 1.45× | 2.08× | 23.5% |
| FY2020 | -2.6% | 1.88× | 1.80× | -8.7% |
| FY2019 | -2.7% | 2.64× | 1.47× | -10.4% |
| FY2018 | 3.8% | 2.77× | 1.58× | 16.8% |
| FY2017 | -8.2% | 2.58× | 1.61× | -34.2% |
| FY2016 | -9.4% | 2.19× | 1.49× | -30.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$220.20K
- Cash generatingOperating cash flow above zero-$54.95K
- Return on assets improvedROA up on the prior year-16.7% → -5.8%
- Earnings backed by cashOperating cash flow above net income-$54.95K vs -$220.20K
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.27 → 1.66
- No dilutionShare count did not rise12M → 12M
- Gross margin improvedGross margin up on the prior year47.62% → 53.56%
- More efficientAsset turnover rose1.59 → 1.72